Ziagen

A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube
AIDS virusZiagen belongs to a class of anti-HIV drugs called Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs). For a description of the life-cycle of the AIDS virus, and the targets of each class of drugs, click here.

Ziagen is marketed by ViiV Healthcare.

AIDS drugs chartOur quick-reference chart allows you to compare all the currently available anti-HIV drugs, including dosing, side effects, & dietary restrictions.
news Treatment News
Search for recent news and archived stories about Ziagen.
forumsHave more questions? Then post a question or comment in our Community Forums.
Help Paying for MedsHelp Paying for Meds: Patient assistance and co-pay programs for HIV and viral hepatitis drugs.
Lessons Our Lessons: Check out our informative Lessons covering various topics to help you make treatment decisions.
Collapse All

Recommended Reading List:

Books about AIDS & HIV treatmentsFor a list of great books about living with HIV and making informed treatment decisions, along with easy links to buy them from Amazon.com, click here.

Ziagen (abacavir)

Pronunciation(s): ZEYE-uh-jen; uh-BACK-ah-veer



What is Ziagen?
  • Ziagen is an HIV medication. It is in a category of HIV medications called nucleoside reverse transcriptase inhibitors (NRTIs). Ziagen prevents HIV from altering the genetic material of healthy CD4 cells. This prevents the cells from producing new virus and decreases the amount of virus in the body.
     
  • Ziagen, manufactured by ViiV Healthcare, was approved for the treatment of HIV by the U.S. Food and Drug Administration (FDA) in 1998.
     
  • Ziagen is available in pharmacies as a single drug, which is always combined with at least two other HIV drugs, or in combination tablets: Trizivir and Epzicom. Each Trizivir tablet contains a single dose of Ziagen, Retrovir (zidovudine), and Epivir (lamivudine). Each Epzicom tablet contains a single dose of Ziagen and Epivir.
     
  • A patient assistance program (PAP) has been established for people living with HIV who do not have private or public health insurance and are unable to afford Ziagen. To learn more about the PAP for Ziagen, call 877-784-4842 or refer to the program's website for more information. For those with private health insurance, GSK has established a program to help cover each Ziagen co-payment, up to $100 every month. To learn more about this co-pay program, check out mysupportcard.com.

What is known about Ziagen?
  • Ziagen can be taken once a day or twice a day. Once-a-day dosing requires taking two 300mg tablets every 24 hours. Twice-a-day dosing requires taking one 300mg tablet every 12 hours. Trizivir tablets, which contain Ziagen, Retrovir, and Epivir are taken twice a day: one tablet in the morning and one tablet in the evening. Epzicom tablets, containing Ziagen and Epivir, are taken once a day.
     
  • For children, a scored tablet and a liquid formula of Ziagen are available. The correct dose depends on the child's body weight and will change as the child gets older. To learn about treatment options for children, click here.
     
  • Ziagen can be taken with or without food.
     
  • Numerous studies have demonstrated that Ziagen is effective for the treatment of HIV when combined with other HIV drugs. Ziagen should not be taken alone (as monotherapy) or with just one other HIV drug.
     
  • For HIV-positive adults beginning HIV drug therapy for the first time, Ziagen is listed as an "alternative" NRTI option by the United States Department of Health and Human Services in its treatment guidelines. Tenofovir and emtricitabine, used together as Truvada or as a part of Atripla (efavirenz, tenofovir and emtricitabine), is listed as the "preferred" dual-NRTI option. To learn more about these recommendations and options, click here.
     
  • Therapy with Ziagen can cause certain changes (mutations) in HIV's structure to occur. Some mutations will prevent Ziagen from working against HIV. Some of these mutations can also prevent Retrovir and/or Epivir from working against HIV. Similarly, Ziagen might not work well against HIV strains already resistant to Retrovir and/or Epivir. If your viral load does not go undetectable or becomes detectable (and increases) while you are taking an HIV drug regimen that contains Ziagen, your doctor can order a drug-resistance test to determine if your HIV has mutations that are causing resistance to Ziagen and to help you figure out which NRTIs your HIV is still sensitive to.

What about drug interactions?
  • Ziagen should not be taken at the same time as Epzicom or Trizivir.
     
  • The protease inhibitor Aptivus (tipranavir) can decrease the amount of Ziagen in the blood. The appropriate doses for this combination have not been established.
     
  • Ziagen can increase the rate at which methadone, a drug often used to help manage symptoms of heroin withdrawal, is cleared from the body. If you are taking methadone and Ziagen at the same time, it might be necessary to increase your methadone dose.

What about side effects?
  • Approximately 5 percent of people who take Ziagen are allergic to it and can experience a "hypersensitivity reaction." This can be serious and may require that Ziagen therapy be stopped. A hypersensitivity reaction usually appears during the second week of therapy, but it can take as long as six weeks to notice any symptoms. The most common symptoms are fever and rash, followed by headaches, stomach upset, feeling tired, sore throat, cough, and shortness of breath. These symptoms usually get worse over time and it is important that you report them to your doctor immediately.

    An inexpensive laboratory test is available to look for an inherited gene, called HLA-B*5701, that has been linked to the hypersensitivity reaction in HIV-positive people taking Ziagen. While not all people with this gene experience an allergic reaction while taking Ziagen, most do. In turn, if you are tested and found to have this gene, Ziagen (or other medications containing abacavir) should either be avoided or used with caution. If you and your doctor are thinking about starting Ziagen or another abacavir-containing medication for the first time, be sure to discuss this genetic test.
     
  • If your doctor tells you that you are allergic or are having a hypersensitivity reaction, you will be told to stop the drug. If you stop taking Ziagen because of these symptoms, you must not start the drug again, or start any drug that contains Ziagen (e.g. Trizivir or Epzicom). Some people who were allergic to the drug and restarted therapy saw their symptoms return immediately and became very ill.
     
  • Lactic acidosis, which can be fatal, and severe liver problems have been reported in people taking NRTIs including Ziagen. Contact your doctor immediately if you experience nausea, vomiting, or unusual or unexpected stomach discomfort; weakness and tiredness; shortness of breath; weakness in the arms and legs; yellowing of the skin or eyes; or pain in the upper stomach area.
     
  • Some of the more common side effects include appetite loss, headaches, feeling crummy (malaise), nausea, vomiting, and diarrhea. Very often, these side effects improve within a few months/weeks of starting Ziagen.
     
  • HIV drug regimens containing NRTIs, including Ziagen, can cause increased fat levels (cholesterol and triglycerides) in the blood, abnormal body-shape changes (lipodystrophy; including increased fat around the abdomen, breasts, and back of the neck, as well as decreased fat in the face, arms, and legs), and diabetes. These side effects of HIV drug therapy are reviewed in our lessons on Lipodystrophy, Facial Lipoatrophy, and Risks To Your Heart (Hyperlipidemia).
     
  • Taking medications that include Ziagen may increase the risk of a heart attack. The reason for the increased risk associated with Ziagen, compared with other NRTIs, has not been established. The risk of a heart attack is highest among people living with HIV taking Ziagen who have other cardiovascular disease (CVD) factors, including high blood pressure, high lipids, diabetes, cigarette smoking, family history of CVD.


Can pregnant women take Ziagen?

  • Ziagen is classified by the FDA as a pregnancy category C drug. Pregnancy category C means that animal studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. HIV-positive women who become pregnant should discuss the benefits and possible side effects of HIV treatment to help protect their babies from HIV (see our lesson called Family Planning, Pregnancy & HIV).
     
  • It is not known whether Ziagen passes into breast milk and what effects it may have on a nursing baby. However, to prevent HIV transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.

Who should not take Ziagen?

  • Before taking this medication, tell your doctor if you have kidney disease or liver disease.
     
  • You may not be able to take Ziagen, or you may require lower doses or special monitoring during treatment, if you have any of these conditions.
     
  • Be sure to tell your doctor if you have allergies to medications, including Ziagen. If you've ever taken Ziagen in the past and stopped the drug for any reason, be sure to tell your doctor. If you have ever taken Ziagen, or any drug that contains Ziagen (e.g. Trizivir or Epzicom), in the past and had a hypersensitivity reaction, you must not take Ziagen again.

Where can I learn more about clinical trials that are using Ziagen?
  • If you would like to find out if you are eligible for any clinical trials that include Ziagen, visit ClinicalTrials.gov, a site run by the U.S. National Institutes of Health. The site has information about all HIV-related clinical studies in the United States. For more info, you can call their toll-free number at 1-800-HIV-0440 (1-800-448-0440) or email contactus@aidsinfo.nih.gov.

Last Revised: February 07, 2011

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.